1. Introduction
Cancer is one of the most lethal diseases and tumor-related morbidity and mortality have significantly increased in recent years with breast cancer (BC) being the most frequent cancer in women worldwide. Three main biological subtypes with distinct genetic, molecular, and clinical relevance have been defined: those expressing estrogen (ER+) and progesterone receptors (PR+), those overexpressing human epidermal growth factor receptor 2 (HER2+), with or without ER+, and those defined by the absence of all these receptors, called triple-negative breast cancer (TNBC) [
1,
2]. ER and HER2 are also therapeutic targets, which may be exploited in addition to radio/chemotherapy if needed. TNBC has no targeted therapy as no druggable molecular targets have been identified yet and is therefore treated only with radio/chemotherapy [
3]. TNBC represents between 10 and 20% of all breast cancers, has high relapse rates early after initial therapy, and has currently the worst prognosis of all subtypes [
4]; thus, the new biological and target agents have to be identified starting from the basic characterization and subtypes. Therapeutic options are mainly limited to surgery, radiation therapy, and conventional chemotherapy using highly toxic compounds with a consequent high incidence of unwanted side effects on healthy tissues. The low efficiency is also responsible for de novo and/or acquired resistance to classical chemotherapeutic regimens [
5]. As a matter of fact, the development of therapy-resistant metastases in vital organs, in particular the liver, lung, and brain, is the main cause of death in relapsing patients [
6]. Actually, there are some new treatments in the pipelines and the first targeted therapy for metastatic TNBC has been approved in April 2020 [
7]. Among the classical drugs used in TNBC treatment, Doxorubicin (Doxo) is one of the most widely used, including the liposomal form. Doxo vectorization reduces its cardiotoxicity and increases the sensitivity of cancer cells to the drug [
8]. In one recent clinical trial combining Abraxane (Paclitaxel) with carboplatin or carboplatin and bevacizumab, most of the participants had serious adverse effects with no benefits [
4]. The current scenario of clinical trials in TNBC is rather grim and improving treatments remains an overwhelming clinical need [
9].
Nanotechnology is expected to have a significant impact, reducing the total amount of the administered drug while increasing the amount delivered to the target, thereby limiting the emergence of drug resistance and allowing the use of highly toxic compounds. Targeted nanocarriers are expected to improve their use and efficacy through multiple mechanisms: (i) protecting drugs from degradation, (ii) modifying pharmacokinetics and drug tissue distribution profiles, (iii) enhancing drug absorption, (iv) improving intracellular penetration and distribution, (v) offering novel imaging opportunities with high performances (specificity, sensitivity, contrast) for the in vivo cancer diagnosis and drug biodistribution. Novel drug delivery tools exploit a combination of chemotherapy and other moieties that are loaded in the same nanocarrier with the advantage of a timely and spatially controlled co-delivery of well-defined relative amounts of several compounds, intended to trigger synergistic effects via different pathways and should therefore increase their individual efficacy [
10]. To develop precise tumor treatments, on-demand strategies exploiting the tumor microenvironment features represent an important opportunity. Nanomaterials spontaneously changing their shape and size based on specific physiological stimuli may increase drug diffusion and accumulation. These features include the overexpression of some enzymes only in certain tumors and the slightly acidic microenvironment (pH 6.0–7.2) which is related to the increased glycolysis and production of lactic acid.
Self-assembled peptide vectors customized with multiple components to optimize drug delivery efficiency represent an alternative strategy in the development of biomaterials with great potential in disease diagnosis and treatment [
11]. Self-assembly in supramolecular materials is an innate ability of peptides, that helps to overcome the low peptide stability which often severely hinders their application in biomedicine. Self-assembly is a relatively straightforward strategy in which peptides spontaneously organize and convert into structurally well-defined and stabilized arrangements via non-covalent interactions due to the balance between the amphiphilic components themselves and the interaction with their environment. The peptide self-assembling process is influenced by solution conditions (such as ionic strength, pH, and assembling rate) as well as a variety of driving forces (electrostatic interactions, van der Waals interactions, hydrophobic and hydrophilic interactions, hydrogen bonds). The self-assembled peptides confer resistance to protease degradation and improve the physiological stability of therapeutics. Self-assembling sequences may be attached to other functionalities; making it relatively easy to tune the activity by simply changing the moieties on the surface without modifying the self-assembled nanostructure. The versatility of the platform paves the way to an easy modulation of properties and of the addressed pathology changing the number and/or the nature of the different moieties. We previously developed a self-assembled peptide fiber with antibiofilm activities [
12], that is made of one or more structural peptides, characterized by the presence of an amino acid sequence of aliphatic residues containing a lipidic tail (C19) attached to the ε amino group of a terminal lysine to generate a peptide amphiphile. The N-terminus of the structural peptide is covalently linked to the moieties that are designed to be on the surface of the carrier, while hydrophobic moieties are encapsulated in the fiber.
In this study, the new nanofiber platform has been designed for being applied as a nanovector of anti-TNBC therapeutics, namely of doxorubicin (Doxo). The presence of the peptide gH625 as delivery moiety on the surface of the vector increases cellular uptake and endosomal escape of drugs. gH625 is a cell-penetrating peptide (CPP) able to traverse biological membranes and enhance the efficient transport of different cargoes promoting temporary lipid membrane-reorganizing processes [
13,
14]. gH625 has opened up an avenue in the research of peptides able to interact with membrane bilayers and to be exploited for drug delivery [
15,
16,
17], being a promising solution to reach intracellular uptake of the nanovectors. Doxo was covalently bound to the fiber surface through an on-demand strategy which allows us to release the drug to the target site. The on-demand strategy used herein exploits the changes in the local environment of cancer tissues, which will enable active delivery of the drugs to the cancer tissues/cells to favor the drug release in the target site. In particular, we exploited the presence of over-expressed matrix metalloproteinase 9 (MMP-9) introducing an MMP-9-specific cleavage sequence between the Doxo and the fiber.
In the matrix of our fibers (hypothesized to be around 12 nm in diameter), we encapsulated superparamagnetic iron oxide nanoparticles (SPIONs) of a mean diameter of about 6 nm. The SPIONs allow us to modulate the nanovectors biodistribution (via magnetoporation) and /or drug release (via magnetic heating) using an external alternating magnetic field and to follow their accumulation in tumors with magnetic resonance imaging (MRI). MRI is one of the most powerful, non-invasive medical imaging methods, and SPIONs used as MRI imaging agents increase its sensitivity. Thus, multifunctional vectors containing SPIONs can be used in a cancer theranostic context [
18].
Biodegradation will be the last step in the stimuli-responsive behavior of the nanofibers: after disassembling, their components can be rapidly cleared through the kidney [
19].
Figure 1 shows the schematic composition/structure and the presumable action mechanism of the nanofibers made of self-assembled peptides, with or without SPION that have been produced in the present work.
The nanofibers were characterized in terms of size, morphology, surface charge, uptake by cancer cells, the release of Doxo in the presence of active MMP-9, and the related cytotoxicity. To our knowledge, no similar MMP-9-responsive peptide-based self-assembled carriers have been reported yet and the developed self-assembled peptide vectors may provide a method to achieve the desired personalized medicine for the treatment of several pathologies.
2. Materials and Methods
2.1. Materials
The conventional amino acids, Fmoc-Ala, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly, Fmoc-His(Trt)-OH, Fmoc-Leu, Fmoc-Ser(tBu)-OH, Fmoc-Thr(OtBu)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Cys(Trt)-OH, Fmoc-Pro-OH, were acquired from GL Biochem Ltd. (Shanghai, China). N,N′-diisopropylcarbodiimide (DIC), Oxyma pure, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), N,N-Diisopropylethylamine, triisopropylsilane (TIS), 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP), nonadecanoic acid (C19) were purchased from Sigma-Aldrich (Italy). Rink amide p-methylbenzhydrylamine (MBHA) resin, Fmoc-L-Lys(Mtt)-OH, piperidine, and trifluoroacetic acid (TFA) were purchased from Iris Biotech GmbH (Marktredwitz, Germany). Anhydrous solvents [N,N-dimethylformamide (DMF) and dichloromethane (DCM)], Doxo-EMCH, matrix metalloproteinase-9 (MMP-9) and dialysis tubing benzoylated, Nile Red, and Thioflavin T were purchased from Sigma-Aldrich (Milan, Italy). Silver nitrate (AgNO3), and trisodium citrate were obtained from Sigma-Aldrich (Luzais, Saint-Quentin-Fallavier, France). Ultrapure water was produced using a Barnstead EASYpure RoDi system (Thermo Fisher Scientific, Villebon sur Yvette, France). All chemicals and reagents were of analytical grade and used as received.
2.2. Peptide Synthesis and Purification
The set of peptides (see the sequences in
Table 1) were synthesized using Rink amide resin as solid support. The Fmoc protecting group was removed by the treatment with a solution of 30% piperidine in DMF (2 × 10 min). Fmoc-Lys(Mtt)-OH was used as the first amino acid for each peptide to perform the conjugation of the lipidic tail (nonadecanoic acid, C19) on the amine group in the lysine side chain. Each reaction coupling was performed through two coupling steps. In the first one, Fmoc-amino acid (4 eq) was added with N,N′-diisopropylcarbodiimide (DIC, 4 eq) oxyma pure (4 eq) as coupling reagents, in DMF for 25 min at rt; in the second one, Fmoc-amino acid (4 eq) was added with HATU (4 eq), DIPEA (8 eq), in DMF for 25 min at rt [
20,
21]. After the assembly of the peptide sequence, the Mtt group of the lysine was removed [
22] to covalently conjugate the tail C19 on the side chain. The Mtt deprotection was performed by treating the resin with the cocktail of DCM:TFA:TIS (94:1:5,
v/
v/
v), 20 × 2min at rt. Once the complete Mtt removal was ascertained by the colorimetric Kaiser test used for the detection of primary amines in a solid phase, the lipid tail C19 was performed using nondecanoic acid (2 eq), DIC (2 eq), oxyma pure (2 eq) in NMP for 2h at rt. The C19 coupling was repeated using HATU (2 eq) and DIPEA (4 eq), in NMP for 2h at rt.
The peptides were cleaved from the resin with an acid solution of TFA/H
2O/TIS (95/2.5/2.5,
v/
v/
v) and in presence of cysteine residues, 1,2-ethanedithiol (EDT) was added (TFA/water/EDT/TIS, 94/2.5/2.5/1,
v/
v/
v/
v,). After 3 h, peptides were precipitated in ice-cold diethyl ether, separated by centrifugation (2 × 15 min, 6000 rpm), and freeze-dried overnight. The peptides were dissolved in H
2O (0.1% TFA) and HFIP (10%) and were purified by RP-HPLC (Shimadzu Preparative Liquid Chromatography LC-8A) on a Phenomenex Jupiter 4 μm Proteo 90 Å 250 × 21.20 mm column, with a linear gradient of solvent B (0.1% TFA in acetonitrile) in solvent A (0.1% TFA in water) from 10 to 90% in 25 min. The yields in purified compounds were approximately 40% for all peptides. The purity and molecular weight of the peptides were determined using LTQ-XL Thermo Scientific linear ion trap mass spectrometer. HPLC spectra and mass measurements are reported in
Figure S1 of Supplementary Information (SI).
2.3. Synthesis and Characterization of Superparamagnetic Iron Oxide Nanoparticles
SPIONs were synthesized as aqueous ferrofluids by a coprecipitation of ferric and ferrous chlorides in an alkaline medium. Briefly, magnetite nanoparticles were precipitated by adding ammonia solution (30 mL, 35%) to an aqueous mixture of Fe
3+ (0.032 mol FeCl
3, 350 mL H
2O) and Fe
2+ (0.016 mol, FeCl
2 20 mL HCl 1.5 M) salts. To stabilize the chemical composition of SPIONs (magnetite/maghemite ratio), after the co-precipitation step, the SPIONs were additionally oxidized using ferric nitrate, thus increasing the surface layer of maghemite. Finally, the SPIONs were peptized in nitric acid and re-suspended in a determined volume of water. The next step consisted of coating the SPIONs with a polysiloxane layer (Sil.SPIONs). For that, 2.20 mL (12.4 mmol) of APS (3-aminopropyltrimethoxysilane) in 10 mL of methanol were added to a mixture of 20 mL (8.8 mmol of iron) of SPIONs and 10 mL of methanol. The mixture was stirred at room temperature for 12 h. To the resulting solution, 20 mL of glycerol was added and methanol then water was removed with a rotary evaporator. After evaporation, the solution was dehydrated in a vacuum at 100 °C for 2 h. The treated nanoparticles were washed three times with 40 mL of water/acetone mixture (30/70
v/
v). Following the addition of 40 mL of water, peptization was performed by slowly decreasing Ph to 3 with 1 M nitric acid under vigorous stirring [
23,
24]. The SPIONs were characterized by dynamic light scattering techniques, while determining their average hydrodynamic diameter (DH) and surface charge (ζ-potential), using Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, UK). All the measurements were performed in triplicate.
2.4. Conjugation of Peptide P4 with Doxo and Characterization by Nuclear Magnetic Resonance Spectroscopy NMR
The cysteine residue in the N-terminus of peptide P4 was exploited for the binding with the maleimide derivative of the Doxo (Doxo-EMCH). In particular, 600 μL of Doxo-EMCH (2.4 mM) in water/dimethylformamide (1:1
v/
v) was mixed gently with 600 μL of peptide P4 (1.2 mM) in PBS using an electromagnetic agitator for 1.5 h at 27 °C in the dark. Doxo-EMCH was added dropwise at 25 μL/min [
25,
26]. Then, the crude compound was lyophilized and purified by dialysis with the membrane MWCO Da11000.
The reaction between P4 peptide and Doxo-EMCH was followed by NMR spectroscopy; NMR spectra were recorded on a Varian Unity Inova 600 MHz spectrometer equipped with a cold probe. Spectra were acquired at 298 K on samples at roughly 200 µM concentration and volumes equal to 500 µL in either DMSO (Dimethyl-Sulfoxide-d6, 99.9% D, Sigma-Aldrich, Milan, Italy) and in D
2O (Deuterium Oxide 99.9% D, Sigma-Aldrich, Milan -. 2D [
1H,
1H] TOCSY (Total Correlation Spectroscopy) [
27] experiments were recorded with mixing times equal to 70 ms with a number of scans ranging from 16 to 64 scans, 128–256 FIDs in t1, 1024 or 2048 data points in t2. NMR spectra were processed with VNMRJ 1.1D (Varian by Agilent Technologies, Milan, Italy); 2D TOCSY spectra were analyzed with the software NEASY [
28] enclosed in CARA (
http://www.nmr.ch/) (accessed on 12 April 2022).
2.5. Formulation of Self-Assembled Nanosystem
To perform experiments, protocols for the preparation of mother solutions of peptides and of their co-assembly into nanofibers were set up. Peptide stock solutions were prepared with two different protocols which were compared. Peptides were dissolved at the highest concentration of 200 µM in water (first protocol) and in HFIP (second protocol). Different aliquots were taken to prepare aqueous solutions of the single peptides or peptide mixtures at different concentrations. In the co-assembled mixtures (P1 + P2, P1 + P3), the peptide molar ratio was 1:1, in trimeric fiber (P1 + P2 + P3) the peptide molar ratio was P1:P2:P3 = 1:0.5:0.5, while in the Doxo containing fiber the peptide molar ratio was P1:P2:P3:P5 = 1:0.8:0.05:0.15 and was kept constant for all experiments. Then, in the first protocol, the solutions were diluted until the concentration was lower than the critical concentration of aggregation and sonicated for 15 min to break any type of pre-existing aggregates; for the second protocol, the solutions were diluted with 1 mL of water and sonicated. All the samples were freeze-dried and hydrated with the proper volume of water, buffer, or dye, in order to obtain the desired concentrations. All the solutions were left to equilibrate for 1 h before use. The two preparations were compared through the calculation of critical aggregation concentrations (CAC) and TEM experiments.
To prepare the nanofibers containing SPIONs, the peptides were dissolved in water in separate solutions at the highest concentration 200µM. The mixtures were prepared to have a µM molar ratio P1:P2:P3:P5 = 1:0.8:0.05:0.15 with a total concentration of 200 μM. The solution was diluted until the concentration was lower than the CAC and sonicated for 15 min to break any type of pre-existing aggregate; then 2 μL of Silanized SPIONs (229 μM of iron) were added at the highest peptide concentration and the solution was freeze-dried.
2.6. Critical Aggregation Concentration (CAC) Determination
CACs of self-assembling peptides were determined by a fluorescence assay with Nile red (NR), a solvatochromic fluorescent probe. NR is poorly water-soluble while displaying a large preference to partition in aggregates that present hydrophobic binding sites and produce a blue shift and hyperchromic effect, which was measured. A methanolic NR solution was prepared at 500 nM. All the samples were freeze-dried and hydrated with the proper volume of NR solution to obtain the desired dye concentrations for the CAC determination by spectrofluorometry. Before fluorescence measurement, all the solutions were left to equilibrate for 1 h. Emission spectra for each solution were measured by a Cary Eclipse Varian spectrometer. The NR emission spectra (exc wavelength 550 nm, emission wavelength range 570 to 700 nm) were measured at least in triplicate for each solution. The data were analyzed by plotting the maximum emission fluorescence corresponding wavelength (y) as a function of peptide concentration (x) and fitting with the sigmoidal Boltzmann equation (OriginPro Program for graphs):
In the equation, A1 and A2 are two variables corresponding to the upper and lower limits of the sigmoid, respectively. Whereas x0 and Δx indicate the inflection point and the steepness of the sigmoid, respectively.
2.7. Zeta Potential Measurements
The zeta potential of different NFs was determined by Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, UK). The measurements were conducted at 25 °C, at pH 7.2. All measurements were performed in triplicate for each sample (
Table 2).
2.8. Structural Characterization by Transmission Electron Microscopy (TEM)
Morphological characterization was performed to analyze the self-assembled peptide nanostructures. Solutions of peptides and their mixtures were freshly prepared in ultrapure water at a concentration higher than their respective CACs. Then, three microliters of each sample were placed on the formvar carbon-coated grid for 1 h and washed with distilled water (three times 10 s). For negative contrast, the samples were incubated in a 2% water solution of uranyl acetate (3 × 10 s, 10 µL) and left to dry in a small drop of the last solution. The micrographs were obtained from JEM 1011 (Jeol Ltd., Tokyo, Japan) equipped with a Gatan digital camera driven by Digital Micrograph software (Gatan Inc., Pleasanton, CA, USA) at 100 kV.
2.9. Self-Assembled System Aggregation Analyses by Thioflavin T Assay
Thioflavin T (ThT) is a benzothiazole dye that exhibits enhanced fluorescence (exc/em at 450/482 nm) upon binding with aggregated peptides. The ThT fluorescence intensity was measured at 25 °C, before and after its addition to nanofibers, using a Varian Cary Eclipse fluorescence spectrometer. Samples were excited at 450 nm (slit width, 5 nm) and fluorescence emission was recorded at 482 nm (slit width, 10 nm). The NFs were generated by rehydrating the lyophilized peptide samples with 300 µL of water and keeping them for 1h before the measurements. The stock solutions of ThT and of the self-assembled peptide nanofibers were prepared in PBS, at 1.5 × 10−3 M and used to prepare the analytical solutions by dilution in deionized water. Fluorescence signal was recorded for 25 µM ThT alone and in presence of self-assembled nanosystem (P1 + P2 + P3, P1 + P2 + P3 + P5 and P1 + P2 + P3 + P5 + SPION). Controls were recorded using the same concentration of nanosystem in PBS, without ThT.
2.10. Enzymatic Cleavage-Mediated Release of Doxo: Assay in Solution
Doxo release from the self-assembled fiber P1 + P2 + P3 + P5 (fiber total concentration 400 μM and Doxo concentration 100 µM) was evaluated using the matrix metalloproteinase-9 (MMP-9). In particular, the fiber was prepared as reported before and hydrated in the following buffer solution:50 mM HEPES, 200 mM NaCl, 10 mM CaCl
2, and 1 mM ZnCl
2, at pH 7. The MMP-9 used for cleavage was pre-activated by APMA 100 µM and Tris-HCl 50 mM (pH 7.2) and was left at 37 °C for 3 h [
29].
For the release test, 50 µL of the pre-activated enzyme (40 nM) and 100 µL of the self-assembled nanosystem were mixed to prepare samples kept in a thermostatic bath at 37 °C for 30, 60, and 90 min. At the scheduled time intervals, the samples were centrifuged at 13.000 rpm for 30 min and the supernatant was analyzed by UV/vis spectroscopy (NanoDrop™ 2000/2000C, Jasco, Milan, Italy) following absorbance at 480 nm (Doxo). Doxo release was evaluated in absence of MMP-9 at pH 7, 3, and 10.
2.11. Circular Dichroism (CD) Analysis
Self-assembled nanosystem solutions for CD studies were prepared at different concentrations of total peptides and hydrated with water or an appropriate hydration solution for each experiment to be conducted (concentration, ionic strength, and pH). CD spectra were recorded from 195 nm to 260 nm in a Jasco J-810 spectropolarimeter using a 1.0 or 0.1 cm quartz cell at room temperature under a constant flow of nitrogen gas. Other experimental settings were as follows: scan speed of 5 nm/min, the sensitivity of 50 mdeg, time constant of 16 s, and bandwidth of 1 nm. Each spectrum was obtained by averaging three scans and converting the signal to mean molar ellipticity. CD measurements were carried out for the different peptides alone or in combinations at different concentrations, ionic strength, and pH values.
2.12. Preparation of Silver Plasmonic Nanoparticles for SERS Experiments
Aqueous colloids of citrate-coated AgNPs were obtained by heat-mediated reducing of silver in the presence of an excess of trisodium citrate, according to a standard protocol described by Lee and Meisel [
30]. Briefly, 90 mg of silver nitrate was dissolved in 500 mL of pure water and heated until boiling. Then, 10 mL of trisodium citrate (1% m/V) was added droplet by droplet under constant agitation and the solution was kept boiling for 1 h. Silver colloid formation leads to the appearance of a characteristic green-brown color. To protect the suspension from light, aluminum paper was put around the glass vial.
2.13. Fluorescence Confocal Spectroscopy and Spectral Imaging (CSI)
To study the uptake of the nanofibers by cancer cells in vitro, the intrinsic fluorescence of the Doxo was followed by means of the confocal spectral imaging (CSI) technique. Briefly, the CSI consists in recording a full fluorescence spectrum from each point of a scanned optical section of the selected cell and then generating the maps (pseudo-color images) reflecting the distribution of spectral parameters (position, shape, width, intensity) in correlation with biochemical events (accumulation, interaction, metabolism, etc). The cells (SKBR3 or MDA-MB-435 cancer cell lines) were plated at a density of 5 × 104 cells/well onto cover glasses in 24-well plates for 1 or 6 h. After incubation (1 to 6 h) with nanoprobes preliminary adjusted to the Doxo concentration of 5 µM, the cells were washed thrice with PBS and mounted between slide and slipcover. They were analyzed under the 50× LWD objective (numerical aperture 0.75; Olympus, Tokyo, Japan) of a LabRam laser scanning confocal microspectrometer (Horiba SA, Villeneuve d’Ascq, Hauts De France, France) equipped with a 491 nm laser source (Cobolt Calypso™), an automated X–Y–Z scanning stage, a low dispersion grating (300 grooves/mm) and an air-cooled EM CCD detector. The confocality was insured due to a pinhole of 200 µm. The laser power on the samples did not exceed 0.5 mW. No samples photodegradation was observed under the conditions used. For fluorescence spectral images acquisition from living cells, the living cells were placed under a 50× microscope and scanned through their equatorial optical section (scanning step of 0.8 µm). The full fluorescence spectrum was recorded from each scanned point (typically 30 × 30 spectra per cell, 0.05 s per spectrum). The same microspectrometer was also used in a non-confocal mode (pinhole of 1000 µm), through a 10× microscope objective (numerical aperture 0.50; LM Plan Fl, Olympus, Japan), in order to record statistically relevant spectra from solutions/suspensions.
The specific fluorescent spectrum of free Doxo at 5 µM in an aqueous solution was compared with that of self-assembled nanofibers (P1 + P2 + P3 + P5 with a concentration of Doxo of 15 µM) dispersed in water. Each spectrum was recorded as an average of 9 scans of 0.1 s. The spectra presented in the figures are the averages of at least three independent measurements. Both measurements and data treatment were performed using the LABSPEC software, version5, by Horiba Scientific (Longjumeau, France).
2.14. SERS Spectra Acquisition
Similar to fluorescence, SERS spectra measurements were carried out using a LabRAM confocal microspectrometer (Horiba Jobin-Yvon, Longjumeau, France) using a 690 nm diode laser source. For SERS, the Ag NPs were aggregated by the addition of 50% of PBS buffer pH 7.4 and mixed with 10% volume of the sample. SERS spectra (region from 300 to 1750 cm−1) were recorded using a 5 µL droplet placed under a 10× microscope objective of the microspectrometer. Spectra presented in the figures are averages of at least three independent measurements. Both experiment control and following data treatment were performed using the LABSPEC software package.
2.15. Cell Culture
The cytotoxicity profiles of the NF-Doxo and NF-Doxo-SPION were established on cancer cell line MDA-MB-231 (triple negative human breast cancer). Triple MDA-MB-231 (ECACC, Salisbury, UK) cells were cultured at 37 °C in an atmosphere containing 5% CO2. The culture medium was made of DMEM supplemented with 10% fetal bovine serum, 1% non-essential amino acid (Hyclone Laboratories, Logan, UT, USA), and 1% penicillin/streptomycin (Gibco®, Life Technologies, Paisley, UK). The cell harvesting was made with trypsin/EDTA (0.05%) (Gibco®, Life Technologies, Paisley, UK) at 80% of confluence.
2.16. Cell Proliferation Assays
Cell viability and proliferation were studied, using a luminescent test based on quantification of ATP, using the CellTiter-Glo cell proliferation assay (Promega, Madison, WI, USA). Briefly, 3.000 MDA-MB-231 cells were incubated in 100 μL of medium in 96-well plates for 24 h and then treated with different samples. A H2O2 solution at 10 mM was used as positive control and the culture medium alone was tested as a negative control. Doxo (stock solution at 5.24 mM in PBS) was used as a reference. Cells were treated with NF-Doxo or NF-Doxo-SPION diluted in culture media from 0.05 to 5 µM in Doxo. Cells were incubated with 100 μL of each solution at 37 °C with 5% CO2 for 72 h. Cell viability was then determined using CellTiter-Glo reagent (Promega, Madison, WI, USA). Briefly, 100 µL of medium were removed and 100 μL of CellTiter-Glo reagent were added to each well. The plates were shaken for 2 min and then incubated at room temperature for 10 min. The luminescence values were measured with a gain at 135, with an acquisition at 0.5 s, using a microplate reader (Bio-Tek® instruments, Inc., VT, Santa Clara, CA, USA). When a dose-dependent activity was observed, 50% inhibitory concentration (IC50) was calculated using Graphpad PRISM 7 software (San Diego, CA, USA) (n = 4 in quadruplicate).
2.17. Effect of the Magnetic Field on the Nanofibers Containing SPIONs
The effect of the magnetic field was studied on SPION-free and SPION-containing nanofibers, without or with 5 µM P3. A range of 4 µL drops of the 4 samples was placed on a glass slide parallel to the rectangular-shape stationary magnet and allowed to dry overnight at room temperature. In this way, the magnetically-attracted SPIONs and nanofibers would form a deposit with a gradient increasing on the magnet side. The aggregated material deposit observable with white light illumination under a 10 objective of the LabRaman confocal microspectrometer was interpreted as particle- and/or fiber-related. The Doxo fluorescence observable with 491 nm laser irradiation was interpreted as nanofiber-related. For each drop, two rectangular zones of the same dimension (35 × 230 µm), one situated on the side close to the magnet and another on the side opposite to the magnet, were scanned to record a spectral map of Doxo fluorescence (0.1 s per spectrum, 5 µm step between spectra). The maps were used to calculate the average fluorescence intensity of the zone.